NeuroGen Pharma

NeuroGen Pharma was founded at the end of 2024, originating from the joint acquisition by CBC Group and Mubadala Investment Company of UCB's mature neuroscience and anti-allergy business in China. This acquisition includes several well-known brands under UCB, such as Keppra®, Vimpat®, Neupro®, Zyrtec®, Xyzal®, as well as a production base located in Zhuhai.Since its establishment, NeuroGen Pharma has been led by an experienced management team with an outstanding track record in the pharmaceutical industry, laying a solid foundation for the company’s future development. NeuroGen Pharma is committed to providing high-quality treatment solutions driven by cutting-edge research and innovation, aiming to meet evolving patient needs and improve therapeutic outcomes in the fields of neurology and pain management.